Phase II, multi-center, open-label, single-arm clinical trial evaluating the efficacy and safety of Mycophenolate Mofetil in patients with high-grade locally advanced or metastatic osteosarcoma (ESMMO): rationale and design of the ESMMO trial

Phase II, multi-center, open-label, single-arm clinical trial evaluating the efficacy and safety of Mycophenolate Mofetil in patients with high-grade locally advanced or metastatic osteosarcoma (ESMMO): rationale and design of the ESMMO trial

Abstract Background Clinical outcomes of patients with osteosarcoma remain unsatisfactory, with little improvement in a 5-year overall survival over the past three decades. There is a substantial need for further research and development to identify and develop more efficacious agents/regimens in or...

Full description

Bibliographic Details
Main Authors: Nut Koonrungsesomboon, Nuttapong Ngamphaiboon, Natavudh Townamchai, Pimpisa Teeyakasem, Chaiyut Charoentum, Pimlak Charoenkwan, Rungrote Natesirinilkul, Lalita Sathitsamitphong, Touch Ativitavas, Parunya Chaiyawat, Jeerawan Klangjorhor, Suradej Hongeng, Dumnoensun Pruksakorn
Format: Article
Language:English
Published: BMC 2020-03-01
Series:BMC Cancer
Subjects:
Osteosarcoma
Mycophenolate mofetil
Phase II
Clinical trial
Cancer
Online Access:http://link.springer.com/article/10.1186/s12885-020-06751-2

Internet

http://link.springer.com/article/10.1186/s12885-020-06751-2

Similar Items